Gossamer Bio, Inc. (NASDAQ:GOSS) has been given an average recommendation of “Buy” by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $22.80.
Several equities analysts have recently issued reports on GOSS shares. HC Wainwright restated a “buy” rating and set a $24.00 price objective (up previously from $15.00) on shares of Gossamer Bio in a report on Thursday, December 17th. Zacks Investment Research downgraded shares of Gossamer Bio from a “buy” rating to a “hold” rating in a report on Tuesday, January 12th.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. boosted its position in Gossamer Bio by 1.3% in the fourth quarter. BlackRock Inc. now owns 4,702,035 shares of the company’s stock valued at $45,469,000 after buying an additional 62,411 shares during the last quarter. Federated Hermes Inc. boosted its position in Gossamer Bio by 71.6% in the fourth quarter. Federated Hermes Inc. now owns 3,464,480 shares of the company’s stock valued at $33,502,000 after buying an additional 1,445,443 shares during the last quarter. State Street Corp boosted its position in Gossamer Bio by 13.4% in the third quarter. State Street Corp now owns 2,154,989 shares of the company’s stock valued at $26,743,000 after buying an additional 254,417 shares during the last quarter. Victory Capital Management Inc. boosted its position in Gossamer Bio by 19.7% in the third quarter. Victory Capital Management Inc. now owns 1,770,016 shares of the company’s stock valued at $21,966,000 after buying an additional 291,456 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in Gossamer Bio by 0.4% in the 3rd quarter. Jennison Associates LLC now owns 1,476,643 shares of the company’s stock worth $18,325,000 after purchasing an additional 5,335 shares in the last quarter. Hedge funds and other institutional investors own 71.96% of the company’s stock.
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial.
See Also: Percentage Gainers
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.